Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 4.2/5
Imeik Technology Development C (300896 CH)
Watchlist
Contact IR
59
Analysis
Health Care
•
China
Imeik Technology Development Co,,Ltd. manufactures and distributes biomedical products. The Company produces sodium hyaluronate, collagens, polylactic acids, and other related products. Imeik Technology Development also produces medical devices.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Alibaba Group Holding
•
11 Jan 2023 01:50
Aequitas 2023 Asia IPO Pipeline - Hong Kong
In this note, we will take a look at the Asia Pacific IPO pipeline for 2023, starting with Hong Kong. The deals you see are only a part of the...
Sumeet Singh
Follow
588 Views
Share
bearish
•
Beauty Farm Medical and Health Industry
•
28 Dec 2022 00:55
Pre-IPO Beauty Farm Medical and Health Industry - Hard to Make Money Due to Industry Characteristics
As a downstream company, Beauty Farm has weak bargaining power in the whole industrial chain.We are conservative about its profitability. The...
Xinyao (Criss) Wang
Follow
816 Views
Share
bullish
•
Giant Biogene
•
03 Nov 2022 01:50
Giant Biogene IPO Trading - Demand Was Relatively Better but Still Weak
Giant Biogene (GB) raised around US$70m by pricing its HK IPO at the low-end. In this note we talk about the trading dynamics.
Sumeet Singh
Follow
327 Views
Share
bullish
•
Giant Biogene
•
25 Oct 2022 03:17
Giant Biogene IPO - Reasonable Valuation but in Unreasonable Markets
Giant Biogene is now looking to raise around US$80m in its Hong Kong IPO, down from its earlier target of US$500m raising.
Sumeet Singh
Follow
354 Views
Share
bullish
•
Giant Biogene
•
19 Oct 2022 01:51
Giant Biogene Pre-IPO - Thoughts on Valuation
Giant Biogene Holding (GBH HK) aims to raise around US$500m in its Hong Kong IPO. In this note, we talk about valuations.
Sumeet Singh
Follow
349 Views
Share
First
Previous
1
2
3
4
5
6
7
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.9
x